Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTM-1632
- Development stage
- Phase 1
- Lead developer
- Ology Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NTM-1632 is an equimolar mixture of three human IgG monoclonal antibodies (B1, B2, and B3) specifically designed to neutralize botulinum neurotoxin serotype B (BoNT/B). Each antibody binds a distinct nonoverlapping epitope on BoNT/B. The mechanism of action involves high-affinity binding to the toxin, blockade of cellular binding epitopes on the toxin, and increased hepatic clearance of toxin-antibody immune complexes. Developed as a potential treatment and postexposure prophylaxis for botulism caused by BoNT/B, NTM-1632 has demonstrated favorable safety, pharmacokinetics (with a half-life >20 days at higher doses), and low immunogenicity in phase 1 clinical trials in healthy adults[1][2][4].
- Other names
- anti-BoNT/B monoclonal antibody mixture
02
Targets
BoNT/B (Botulinum neurotoxin type B)
Beyond the preview
Go deeper on NTM-1632.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTM-1632.